NEW TEST: GENESTRAT (BIODESIX)
- FLASCO
- May 21, 2015
- Drugs
NEW TEST: GENESTRAT (BIODESIX)
Biodesix is pleased to announce the launch of GeneStrat, a liquid biopsy mutation test for genotyping tumors of NSCLC patients, is an exciting milestone for Biodesix. The combined diagnostic power of GeneStrat and VeriStrat will continue to help assist physicians in treating their patients by offering more information in a timely manner, results being returned within 72 hours of shipment of the sample.
The press release for GeneStrat can also be found at the following link: http://www.biodesix.com/biodesix-launches-genestrat-targeted-liquid-biopsy-mutation-test-for-patients-with-advanced-lung-cancer/
